Octant Began Phase 1b/2 Trial for Retinitis Pigmentosa Drug
The investigational oral drug OCT-980 aims to treat a rare inherited retinal disease that currently lacks any approved therapy.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Should medical research prioritize developing new drug treatments for rare diseases?
Drug discovery firm Octant has administered the first dose of its investigational small molecule OCT-980 to a patient in a Phase 1b/2 clinical trial. This research-stage study targets rhodopsin-associated autosomal dominant retinitis pigmentosa, a condition characterized by progressive vision loss with no existing medical treatment.
Why it matters
By targeting the underlying mechanism of protein misfolding, OCT-980 represents a potential breakthrough for patients with RHO-adRP. The study is currently moving beyond initial healthy volunteer testing to assess therapeutic efficacy in the target patient population.
The study, registered as NCT07408232, is evaluating the safety, pharmacokinetics, and pharmacodynamics of the oral molecule. The trial aims to determine if the drug effectively stabilizes misfolded rhodopsin to restore proper cellular trafficking.
The players
Octant
A drug discovery company based in Emeryville, California, that uses proprietary platforms to engineer and develop novel small molecule therapeutics.
The details
OCT-980 is an oral small molecule designed to address RHO-adRP by binding to and stabilizing misfolded rhodopsin, a light-sensitive protein in the retina. By correcting these misfolded proteins, the therapy seeks to restore normal cellular trafficking, or the movement of molecules within and across cell membranes. Researchers aim to quantify if this process improves low-light vision and slows or halts the progression of the inherited retinal disease.
Timeline
September 25, 2026: Octant announced that the first patient received a dose.
The Tech Race
This trial advances the broader research push to develop disease-modifying therapies for inherited retinal conditions like RHO-adRP. Octant is now moving toward clinical data generation in a space where no other pharmaceutical interventions currently exist.
Patients and families affected by RHO-adRP should monitor the progress of this multi-center Phase 1b/2 trial for initial safety and efficacy results. As an investigational drug, OCT-980 is not available for clinical use, and future availability depends entirely on the successful completion of subsequent clinical milestones.
The takeaway
Octant is testing whether stabilizing proteins can halt vision loss in patients with no alternative care options. Observers should track the release of data from this multi-center study to determine if the therapeutic approach successfully translates into improved patient outcomes.
Further reading
For broader trends in molecular medicine and drug development, explore our Biotech coverage.
More information
View full trial details at the clinical study information registry page.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should medical research prioritize developing new drug treatments for rare diseases?
